Adagene Inc. - notizie pubblicate 51 - letture 1.634
ADAGENE INC.
Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update
- potential best-in-class therapeutic index for lead candidate anti-ctla-4 safebody® adg126 (muzastotug) with higher, more frequent and repeat dosing in combination with merck's a ...
ADAGENE INC.
Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update Form 6 K
Adagene reports six month financial results for 2024 and provides corporate update - potential best-in-class therapeutic index for lead candidate anti-ctla-4 safebody® adg126 (muz ...
ADAGENE INC.
Adagene to Present at Investor Conferences in June
San diego and suzhou, china, may 22, 2024 (globe newswire) -- adagene inc. ("adagene") (nasdaq: adag), a company transforming the discovery and development of novel antib ...
ADAGENE INC.
Entry into Sales Agreement - Form 6-K
United states securities and exchange commission washington, d.c. 20549 form 6-k report of foreign private issuer pursuant to rule 13a-16 or 15d-16 under the securities exchange ac ...
ADAGENE INC.
Supplemental Prospectus - Form 424B5
Tm2213007-9_424b5 - none - 9.5570855s table of contents as filed pursuant to rule 424(b)(5) registration no. 333-264486 prospectus supplement (to prospectus dated may 26, 2022 ) ad ...
ADAGENE INC.
Annual Report for Fiscal Year Ending December 31, 2023 (Form 20-F)
Table of contents united states securities and exchange commission washington, d.c. 20549 form 20-f (mark one) ☐ registration statement pursuant to section 12(b) or 12(g) of the ...
ADAGENE INC.
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update
- data for masked anti-ctla-4 safebody® adg126 (muzastotug) highlight best-in-class therapeutic index and demonstrate clinical benefits in metastatic microsatellite-stable (mss) c ...
ADAGENE INC.
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update - Form 6-K
Adagene reports full year 2023 financial results and provides corporate update - data for masked anti-ctla-4 safebody® adg126 (muzastotug) highlight best-in-class therapeutic inde ...
ADAGENE INC.
Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board
- global oncology expert brings deep insight in colorectal cancer and role of ctla-4 therapy as a cornerstone for combination immunotherapy - san diego and suzhou, china, march 07, ...
ADAGENE INC.
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024
San diego and suzhou, china, feb. 27, 2024 (globe newswire) -- adagene inc. ("adagene") (nasdaq: adag), a company transforming the discovery and development of novel anti ...
ADAGENE INC.
Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) - Form 6-K
Adagene announces progress and expansion of clinical collaboration program for masked, anti-ctla-4 safebody® adg126 (muzastotug) in combination with keytruda® (pembrolizumab) to ...
ADAGENE INC.
Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
- interim data from additional mss crc patients dosed at 10 mg/kg every three weeks (q3w) in combination with pembrolizumab anticipated in 2024 at a medical conference - - initiate ...
ADAGENE INC.
ADG126 - ASCO-GI 2024 Data Summary
Results of a phase 1b/2 study of adg126 (a masked anti-ctla-4 safebody®) in combination with pembrolizumab (pembro) in patients with metastatic microsatellite-stable (mss) colorec ...
ADAGENE INC.
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) - Form 6-K
Adagene presents interim results reinforcing best-in-class profile of masked anti-ctla-4 safebody® adg126 (muzastotug) in combination with pembrolizumab in metastatic microsatel ...
ADAGENE INC.
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
- data from first tranche of mss crc patients treated with adg126 10 mg/kg every three weeks (q3w) in dose expansion showed clinical benefit including confirmed responses at higher ...
Sei un professionista?
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti